Acceleron Pharma

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or “us”) beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron,” “XLRN” or the “Company”), making Avoro one of the Company's most significant shareholders. Avoro today issued the following statement reiterating why it believes that shareholders sh

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer

Merck

There's nothing to worry about with a recent delay.

Is Merck's Planned Acquisition of Acceleron in Trouble?

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron”, “XLRN” or the “Company”), making Avoro one of the Company's most significant shareholders. Avoro today released a detailed presentation outlining why shareholders should not tender t

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer

Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021. Corporate Highlights On September 30, Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. announced that the companies entered into a defi

Acceleron Reports Third Quarter 2021 Financial Results

Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)

Dawson Geophysical

Flexion Therapeutics

PAE Inc

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Dawson Geophysical Company (NASDAQ: DWSN) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dawson Geophysical Company (NASDAQ: DWSN) in connection with the proposed acquisition of DWSN by a subsidiary of Wilks Brothers, LLC.

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations

Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today.

Merck Pushes Acceleron Buyout By Refiling For Antitrust Review

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq:XLRN) (“Acceleron”, “XLRN” or the “Company”) together with certain of its affiliates and managed funds (“Avoro,” “we” or "us"), making it one of the Company's most significant shareholders. Avoro today issued an open letter to fellow Acceleron shareholders further detailing why the pr

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $160 million for the third quarter ended September 30, 2021. Net sales of REBLOZYL for the third quarter include approximat

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

Great Western Bancorp

HollyFrontier

Meredith

NEW YORK, Oct. 22, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY  10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Meredith Corporation (NYSE: MDP) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meredith Corporation (NYSE: MDP) in connection with the proposed acquisition of the company by IAC/InterActiveCorp.  Under the terms of the merger agreement, MDP shareholders will receive $42.18 per share in cash for each share of MDP common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations

Bristol-Myers

Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter. Bristol-Myers holds an 11.5% stake in Acceleron.

Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg

JERSEY, Channel Islands--(BUSINESS WIRE)--Darwin Global Management Limited (“Darwin Global”), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 shares of common stock of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”), representing approximately 3.84% of the total outstanding shares of the Company's common stock, today issued the following letter to Acceleron shareholders. In the letter, Darwin Global urges shareholders not

Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to Merck

NEW YORK--(BUSINESS WIRE)-- #Acceleron--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. (NASDAQ: XLRN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Merck & Co., Inc. (NYSE: MRK). Click here to learn more and participate in the action. On September 30, 2021, Acceleron announced that it had entered int

ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares

NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Acceleron Pharma Inc. ( XLRN ) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own. The investigation focuses on whether Acceleron Pharma Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN

Investment management firm Holocene Advisors said it will not tender its shares in Acceleron Pharma Inc into Merck & Co's proposed $180 per share offer for the drugmaker, as it significantly undervalues the company.

Holocene Advisors says Merck's offer undervalues Acceleron

NEW YORK--(BUSINESS WIRE)--Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”), today announced that it does not intend to tender its shares into Merck & Co.'s (NYSE: MRK) proposed $180 per share offer for the Company announced on September 30, 2021. Holocene stated the following: “As a large shareholder in Acceleron, we believe the Company's management team has done a

Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company

Merck will pick up a promising pipeline candidate with the deal.

Is an Acquisition of Acceleron a Smart Move for Merck?

New York, New York--(Newsfile Corp. - October 4, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Acceleron Pharma Inc. (NASDAQ: XLRN) ("Acceleron" or "Company") stock prior to September 30, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Acceleron with Merck & Co., Inc. Under the terms of the

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Acceleron Pharma Inc. with Merck & Co., Inc.

Merck yesterday announced that it will acquire Acceleron Pharma - a biopharmaceutical company focused on rare diseases - for $11.5 billion funded in cash and debt. Acceleron has multiple potentially blockbuster drugs in its pipeline.

With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acceleron Pharma Inc. (NasdaqGM: XLRN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Acceleron will receive only $180 in cash for each share of Acceleron that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or wh

ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acceleron Pharma Inc. - XLRN

Hours after Merck & Co Inc's (NYSE: MRK) announcement to acquire Acceleron Pharma Inc (NASDAQ: XLRN), one of Acceleron's activist investors isn't happy with the price tag. Related:   Merck Seals Acceleron Pharma Deal For $180/Share: Highlights.

Activist Investor Thinks Merck Undervalues Acceleron Buy

Regeneron Pharmaceuticals

Core PCE Inflation Stays at Record-High in August.

Core PCE Inflation Stays at Record-High in August

Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.

News for Acceleron Pharma Stock (XLRN)